Durvalumab plus chemotherapy in ES-SCLC (Oriental)

Trial Identifier: D419BR00018
Sponsor: AstraZeneca
NCTID:: NCT04449861
Start Date: December 2020
Primary Completion Date: March 2023
Study Completion Date: March 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Simplified Chinese (China)

Trial Locations

Country Location
CN Baoding, CN, 071000
CN Beijing, CN, 100021
CN Changchun, CN, 130012
CN Chengdu, CN, 610041
CN Dalian, CN, 116001
CN Dongyang, CN, 322100
CN Fuzhou, CN, 350009
CN Guangdong, CN, 510300
CN Guangdong, CN, 510120
CN Guangzhou, CN, 510080
CN Guangzhou, CN, 510120
CN Guangzhou, CN, 510280
CN Haerbin, CN, 150081
CN Hangzhou, CN, 310022
CN Hangzhou, CN, 310016
CN Hefei, CN, 230000
CN Huai'an, CN, 223000
CN Jiangyin, CN, 214400
CN Jinan, CN, 250117
CN Jinhua, CN, 321099
CN Kunming, CN, 650118
CN Nanchang, CN, 330000
CN Nanjing, CN, 210032
CN Ningbo, CN, 315000
CN Qingdao, CN, 266100
CN Shanghai, CN, 200025
CN Shanghai, CN, 200040
CN Shanghai, CN, 200032
CN Shenzhen, CN, 518116
CN ShenZhen, CN, 518020
CN Suzhou, CN, 215000
CN Taiyuan, CN, 030000
CN Taizhou, CN, 318000
CN Tianjin, CN, 300060
CN Whenzhou, CN, 325000
CN Wuhan, CN, 430022
CN Wuxi, CN, 214023
CN Yangzhou, CN, 225012
CN Zhengzhou, CN, 450000